Dmitriy Zamarin

Mount Sinai Hospital — United States

Medicine · Health Sciences

57h-index15.0kcitations377works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(95), Ovarian cancer diagnosis and treatment(81), Endometrial and Cervical Cancer Treatments(69), Cancer Genomics and Diagnostics(50), CAR-T cell therapy research(47)

Publications376 total

Computational Inference of Metabolic Programs: A Case Study Analyzing the Effect of BRCA1 Loss
2025Open Access
Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer
Nature Immunology·2025· 1 cited
299 Targeting dysregulated wound healing programs in cancer and fibrosis with immune engineering
Regular and Young Investigator Award Abstracts·2025Open Access
A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer
Gynecologic Oncology·2025Open Access
Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer
Brachytherapy·2025
Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA
Nature·2025· 4 citedOpen Access
Abstract PR015: Tumor-derived IL-4 links chemotherapy to immunotherapy resistance in ovarian cancer
Cancer Research·2025
Abstract PR012: Targeting Chronic Inflammation in Ovarian Cancer Through Immune Engineering
Cancer Research·2025
Development of a genetically induced syngeneic mouse model of endometrial cancer
Gynecologic Oncology·2025
Perioperative stress reduction in ovarian cancer (PRESERVE)
Gynecologic Oncology·2025
Early-stage uterine papillary serous carcinoma: Clinical outcomes in patients treated with adjuvant chemotherapy and vaginal brachytherapy
Gynecologic Oncology·2025
Ongoing genome doubling shapes evolvability and immunity in ovarian cancer
Nature·2025· 18 citedOpen Access
A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and endometrial cancer.
Journal of Clinical Oncology·2025
Design of a first-in-human multicenter open-label study of ZW171, a mesothelin x CD3 targeting bispecific T-cell engager, in participants with advanced solid tumors: ZWI-ZW171-101.
Journal of Clinical Oncology·2025
Clinicodemographic predictors of enrollment and outcomes in early phase oncology clinical trials in a diverse urban population.
Journal of Clinical Oncology·2025
Unnecessary exclusions: eligibility criteria in gynecologic oncology interventional clinical trials impairs access
International Journal of Gynecological Cancer·2025
Evolution of tumor stress response during cytoreductive surgery for ovarian cancer
iScience·2025· 1 citedOpen Access
A working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era
JNCI Journal of the National Cancer Institute·2025· 3 citedOpen Access
Supplementary Figures from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
2025Open Access
Table S2 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
2025Open Access
page 1 of 19Next →

Frequent Co-authors

Taha Merghoub(14), Jedd D. Wolchok(13), Peter Palese(11), Carol Aghajanian(9), Britta Weigelt(8), Alexandra Snyder(6), Nadeem R. Abu‐Rustum(6), Jorge S. Reis‐Filho(6), Sohrab P. Shah(6), Jacob Ricca(6), Rikke Holmgaard(5), Lora H. Ellenson(5), Michael F. Berger(5), Oliver Zivanovic(5), Adolfo Garcı́a-Sastre(5), Tyler Walther(4), James P. Allison(4), Anuradha Gopalan(4), Jianjiong Gao(4), Ahmet Zehir(4)